BG107774A - Combination of gaba agonists and sorbitol dehydrogenase inhibitors - Google Patents

Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Info

Publication number
BG107774A
BG107774A BG107774A BG10777403A BG107774A BG 107774 A BG107774 A BG 107774A BG 107774 A BG107774 A BG 107774A BG 10777403 A BG10777403 A BG 10777403A BG 107774 A BG107774 A BG 107774A
Authority
BG
Bulgaria
Prior art keywords
diabetic
prodrug
combinations
combination
gaba agonists
Prior art date
Application number
BG107774A
Other languages
Bulgarian (bg)
English (en)
Inventor
Banavara L. Mylari
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107774A publication Critical patent/BG107774A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG107774A 2000-11-30 2003-05-07 Combination of gaba agonists and sorbitol dehydrogenase inhibitors BG107774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
BG107774A true BG107774A (en) 2004-01-30

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107774A BG107774A (en) 2000-11-30 2003-05-07 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Country Status (38)

Country Link
US (1) US6544998B2 (cs)
EP (1) EP1337271B1 (cs)
JP (1) JP2004514699A (cs)
KR (1) KR20030059290A (cs)
CN (1) CN1477975A (cs)
AP (1) AP2001002360A0 (cs)
AR (1) AR031431A1 (cs)
AT (1) ATE281181T1 (cs)
AU (1) AU2002215159A1 (cs)
BG (1) BG107774A (cs)
BR (1) BR0115783A (cs)
CA (1) CA2430298A1 (cs)
CR (1) CR6964A (cs)
CZ (1) CZ20031399A3 (cs)
DE (1) DE60106968T2 (cs)
DO (1) DOP2001000289A (cs)
EA (1) EA200300432A1 (cs)
EC (1) ECSP034624A (cs)
EE (1) EE200300248A (cs)
ES (1) ES2230378T3 (cs)
HR (1) HRP20030420A2 (cs)
HU (1) HUP0302160A3 (cs)
IL (1) IL155704A0 (cs)
IS (1) IS6786A (cs)
MA (1) MA26964A1 (cs)
MX (1) MXPA03004870A (cs)
NO (1) NO20032441L (cs)
OA (1) OA12534A (cs)
PA (1) PA8534101A1 (cs)
PE (1) PE20020597A1 (cs)
PL (1) PL365927A1 (cs)
PT (1) PT1337271E (cs)
SK (1) SK6192003A3 (cs)
SV (1) SV2003000751A (cs)
TN (1) TNSN01169A1 (cs)
UY (1) UY27042A1 (cs)
WO (1) WO2002043762A2 (cs)
ZA (1) ZA200303381B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
OA12604A (en) * 2001-05-25 2006-06-08 Warner Lambert Co Liquid pharmaceutical composition.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
MXPA06011322A (es) * 2004-04-02 2007-02-21 Impax Laboratories Inc Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
DK1849773T3 (da) 2005-02-17 2013-11-04 Astellas Pharma Inc Piperazinderivater til behandlingen af urininkontinens og smerte
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
CA2756791C (en) 2007-04-27 2016-09-13 Purdue Pharma L.P. Trpv1 antagonists and uses thereof
CA2701838A1 (en) * 2007-10-09 2009-04-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
EP3753410A3 (en) * 2010-09-28 2021-04-28 The Regents Of The University Of California Combinations comprising gaba agonists in treatment of hyperglycemia
CA2837178C (en) 2011-06-22 2016-09-20 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955919A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
BR112021021939A2 (pt) * 2019-05-07 2022-02-22 Ucl Business Ltd Tratamento e detecção de neuropatias herdadas e distúrbios associados

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
EP0059987B1 (en) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((n-guanidino)-imino) toluenes
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
AP2005003199A0 (en) * 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
CR6964A (es) 2004-02-02
HUP0302160A3 (en) 2005-05-30
OA12534A (en) 2006-06-05
DE60106968T2 (de) 2005-11-03
CN1477975A (zh) 2004-02-25
CA2430298A1 (en) 2002-06-06
WO2002043762A2 (en) 2002-06-06
EP1337271B1 (en) 2004-11-03
US6544998B2 (en) 2003-04-08
NO20032441L (no) 2003-07-03
HRP20030420A2 (en) 2004-08-31
ZA200303381B (en) 2004-04-30
KR20030059290A (ko) 2003-07-07
HUP0302160A2 (hu) 2003-11-28
CZ20031399A3 (cs) 2004-04-14
IS6786A (is) 2003-04-14
MA26964A1 (fr) 2004-12-20
DE60106968D1 (de) 2004-12-09
ECSP034624A (es) 2003-07-25
SK6192003A3 (en) 2004-07-07
PL365927A1 (en) 2005-01-10
NO20032441D0 (no) 2003-05-28
EE200300248A (et) 2003-10-15
AU2002215159A1 (en) 2002-06-11
TNSN01169A1 (fr) 2005-11-10
AR031431A1 (es) 2003-09-24
PT1337271E (pt) 2005-01-31
WO2002043762A3 (en) 2003-03-13
MXPA03004870A (es) 2003-08-19
ES2230378T3 (es) 2005-05-01
DOP2001000289A (es) 2003-02-15
PA8534101A1 (es) 2002-10-31
EA200300432A1 (ru) 2003-10-30
IL155704A0 (en) 2003-11-23
UY27042A1 (es) 2002-07-31
SV2003000751A (es) 2003-01-13
EP1337271A2 (en) 2003-08-27
AP2001002360A0 (en) 2001-12-31
ATE281181T1 (de) 2004-11-15
US20020091128A1 (en) 2002-07-11
PE20020597A1 (es) 2002-07-08
JP2004514699A (ja) 2004-05-20
BR0115783A (pt) 2003-09-16

Similar Documents

Publication Publication Date Title
BG107774A (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
AP2001002359A0 (en) Combination of gaba agonists and aldose reductase inhibitors.
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
BRPI0809011A8 (pt) composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
ATE440603T1 (de) 8-hydroxychinolinderivate
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
EP1106210A3 (en) Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
AU2003250701A1 (en) Protein tyrosine kinase inhibitors
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
HRP20041150A2 (en) Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
WO2008079728A3 (en) Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
WO2002032411A3 (en) Combination of statins and sorbitol dehydrogenase inhibitors
DK1276722T3 (da) Naphthamidin-urokinaseinhibitorer
EP1260221A3 (en) Combination treatment for depression and anxiety
AU2003280232A1 (en) Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action
ES2173044A1 (es) Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.